Shanghai Pharmaceuticals (02607) terminates the clinical trial and subsequent development of the I025-A R&D project

Zhitong Finance APP news, Shanghai Pharmaceuticals (02607) announced that, in order to rationally allocate R&D resources and focus on advantageous R&D projects, the company, based on a comprehensive assessment of factors such as the future market value of R&D projects, business synergy, and subsequent development investment, has decided to terminate the clinical trials and subsequent development of the I025-A R&D project.